Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn’s disease: a comparative study

Short-term effectiveness and safety of ustekinumab and vedolizumab in elderly and non-elderly patients with Crohn’s disease: a comparative study

Background: Inflammatory bowel disease (IBD) presents unique challenges in elderly patients due to comorbidities and treatment-related risks. Objectives: This study evaluates ustekinumab (UST) and vedolizumab (VDZ) efficacy and safety in elderly Crohn’s disease (CD) patients. Design: A retrospective...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutic advances in gastroenterology 2024-01, Vol.17, p.17562848241299752
Hauptverfasser: Dar, Lior, Shani, Uria, Dotan, Arad, Ukashi, Offir, Ben-Horin, Shomron, Kopylov, Uri, Levartovsky, Asaf
Format: Artikel
Sprache:eng
Schlagworte:
Hospitalization
Inflammatory GI Disorders Unveiled: Mechanisms and Emerging Treatments
Monoclonal antibodies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Inflammatory bowel disease (IBD) presents unique challenges in elderly patients due to comorbidities and treatment-related risks. Objectives: This study evaluates ustekinumab (UST) and vedolizumab (VDZ) efficacy and safety in elderly Crohn’s disease (CD) patients. Design: A retrospective cohort study at a tertiary medical center. Methods: CD patients aged ⩾60 years (elderly) treated with UST, compared to non-elderly (
ISSN:1756-2848
1756-283X
1756-2848
DOI:10.1177/17562848241299752